These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

181 related articles for article (PubMed ID: 29026141)

  • 1. Combined skin and muscle vaccination differentially impact the quality of effector T cell functions: the CUTHIVAC-001 randomized trial.
    Haidari G; Cope A; Miller A; Venables S; Yan C; Ridgers H; Reijonen K; Hannaman D; Spentzou A; Hayes P; Bouliotis G; Vogt A; Joseph S; Combadiere B; McCormack S; Shattock RJ
    Sci Rep; 2017 Oct; 7(1):13011. PubMed ID: 29026141
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Combined Skin and Muscle DNA Priming Provides Enhanced Humoral Responses to a Human Immunodeficency Virus Type 1 Clade C Envelope Vaccine.
    Cheeseman HM; Day S; McFarlane LR; Fleck S; Miller A; Cole T; Sousa-Santos N; Cope A; Cizmeci D; Tolazzi M; Hwekwete E; Hannaman D; Kratochvil S; McKay PF; Chung AW; Kent SJ; Cook A; Scarlatti G; Abraham S; Combadiere B; McCormack S; Lewis DJ; Shattock RJ
    Hum Gene Ther; 2018 Sep; 29(9):1011-1028. PubMed ID: 30027768
    [TBL] [Abstract][Full Text] [Related]  

  • 3. The Safety and Immunogenicity of GTU
    Haidari G; Day S; Wood M; Ridgers H; Cope AV; Fleck S; Yan C; Reijonen K; Hannaman D; Spentzou A; Hayes P; Vogt A; Combadiere B; Cook A; McCormack S; Shattock RJ
    Front Immunol; 2019; 10():2911. PubMed ID: 31921170
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Robust antibody and cellular responses induced by DNA-only vaccination for HIV.
    De Rosa SC; Edupuganti S; Huang Y; Han X; Elizaga M; Swann E; Polakowski L; Kalams SA; Keefer MC; Maenza J; Lu Y; Wise MC; Yan J; Morrow MP; Khan AS; Boyer JD; Humeau L; White S; Pensiero M; Sardesai NY; Bagarazzi ML; Weiner DB; Ferrari G; Tomaras GD; Montefiori DC; Corey L; McElrath MJ;
    JCI Insight; 2020 Jul; 5(13):. PubMed ID: 32437332
    [TBL] [Abstract][Full Text] [Related]  

  • 5. HIV-DNA Given with or without Intradermal Electroporation Is Safe and Highly Immunogenic in Healthy Swedish HIV-1 DNA/MVA Vaccinees: A Phase I Randomized Trial.
    Nilsson C; Hejdeman B; Godoy-Ramirez K; Tecleab T; Scarlatti G; Bråve A; Earl PL; Stout RR; Robb ML; Shattock RJ; Biberfeld G; Sandström E; Wahren B
    PLoS One; 2015; 10(6):e0131748. PubMed ID: 26121679
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Long-term CD4(+) and CD8(+) T-cell responses induced in HIV-uninfected volunteers following intradermal or intramuscular administration of an HIV-lipopeptide vaccine (ANRS VAC16).
    Launay O; Surenaud M; Desaint C; Ben Hamouda N; Pialoux G; Bonnet B; Poizot-Martin I; Gonzales G; Cuzin L; Bourgault-Villada I; Lévy Y; Choppin J; Durier C
    Vaccine; 2013 Sep; 31(40):4406-15. PubMed ID: 23850610
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults.
    Mpendo J; Mutua G; Nyombayire J; Ingabire R; Nanvubya A; Anzala O; Karita E; Hayes P; Kopycinski J; Dally L; Hannaman D; Egan MA; Eldridge JH; Syvertsen K; Lehrman J; Rasmussen B; Gilmour J; Cox JH; Fast PE; Schmidt C
    PLoS One; 2015; 10(8):e0134287. PubMed ID: 26252526
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Preferential amplification of CD8 effector-T cells after transcutaneous application of an inactivated influenza vaccine: a randomized phase I trial.
    Combadière B; Vogt A; Mahé B; Costagliola D; Hadam S; Bonduelle O; Sterry W; Staszewski S; Schaefer H; van der Werf S; Katlama C; Autran B; Blume-Peytavi U
    PLoS One; 2010 May; 5(5):e10818. PubMed ID: 20520820
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Broad and potent immune responses to a low dose intradermal HIV-1 DNA boosted with HIV-1 recombinant MVA among healthy adults in Tanzania.
    Bakari M; Aboud S; Nilsson C; Francis J; Buma D; Moshiro C; Aris EA; Lyamuya EF; Janabi M; Godoy-Ramirez K; Joachim A; Polonis VR; Bråve A; Earl P; Robb M; Marovich M; Wahren B; Pallangyo K; Biberfeld G; Mhalu F; Sandström E
    Vaccine; 2011 Oct; 29(46):8417-28. PubMed ID: 21864626
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Enhanced immunogenicity of an HIV-1 DNA vaccine delivered with electroporation via combined intramuscular and intradermal routes.
    Mann JF; McKay PF; Fiserova A; Klein K; Cope A; Rogers P; Swales J; Seaman MS; Combadiere B; Shattock RJ
    J Virol; 2014 Jun; 88(12):6959-69. PubMed ID: 24719412
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Plasmid DNA vaccination using skin electroporation promotes poly-functional CD4 T-cell responses.
    Bråve A; Nyström S; Roos AK; Applequist SE
    Immunol Cell Biol; 2011 Mar; 89(3):492-6. PubMed ID: 20838412
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Combined effects of IL-12 and electroporation enhances the potency of DNA vaccination in macaques.
    Hirao LA; Wu L; Khan AS; Hokey DA; Yan J; Dai A; Betts MR; Draghia-Akli R; Weiner DB
    Vaccine; 2008 Jun; 26(25):3112-20. PubMed ID: 18430495
    [TBL] [Abstract][Full Text] [Related]  

  • 13. In vivo electroporation enhances the immunogenicity of an HIV-1 DNA vaccine candidate in healthy volunteers.
    Vasan S; Hurley A; Schlesinger SJ; Hannaman D; Gardiner DF; Dugin DP; Boente-Carrera M; Vittorino R; Caskey M; Andersen J; Huang Y; Cox JH; Tarragona-Fiol T; Gill DK; Cheeseman H; Clark L; Dally L; Smith C; Schmidt C; Park HH; Kopycinski JT; Gilmour J; Fast P; Bernard R; Ho DD
    PLoS One; 2011; 6(5):e19252. PubMed ID: 21603651
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Intradermal SynCon® Ebola GP DNA Vaccine Is Temperature Stable and Safely Demonstrates Cellular and Humoral Immunogenicity Advantages in Healthy Volunteers.
    Tebas P; Kraynyak KA; Patel A; Maslow JN; Morrow MP; Sylvester AJ; Knoblock D; Gillespie E; Amante D; Racine T; McMullan T; Jeong M; Roberts CC; Park YK; Boyer J; Broderick KE; Kobinger GP; Bagarazzi M; Weiner DB; Sardesai NY; White SM
    J Infect Dis; 2019 Jul; 220(3):400-410. PubMed ID: 30891607
    [TBL] [Abstract][Full Text] [Related]  

  • 15. High antibody and cellular responses induced to HIV-1 clade C envelope following DNA vaccines delivered by electroporation.
    Yin J; Dai A; Lecureux J; Arango T; Kutzler MA; Yan J; Lewis MG; Khan A; Sardesai NY; Montefiore D; Ruprecht R; Weiner DB; Boyer JD
    Vaccine; 2011 Sep; 29(39):6763-70. PubMed ID: 21195801
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Priming with a Potent HIV-1 DNA Vaccine Frames the Quality of Immune Responses prior to a Poxvirus and Protein Boost.
    Asbach B; Kibler KV; Köstler J; Perdiguero B; Yates NL; Stanfield-Oakley S; Tomaras GD; Kao SF; Foulds KE; Roederer M; Seaman MS; Montefiori DC; Parks R; Ferrari G; Forthal DN; Phogat S; Tartaglia J; Barnett SW; Self SG; Gottardo R; Cristillo AD; Weiss DE; Galmin L; Ding S; Heeney JL; Esteban M; Jacobs BL; Pantaleo G; Wagner R
    J Virol; 2019 Feb; 93(3):. PubMed ID: 30429343
    [TBL] [Abstract][Full Text] [Related]  

  • 17. The site of administration influences both the type and the magnitude of the immune response induced by DNA vaccine electroporation.
    Vandermeulen G; Vanvarenberg K; De Beuckelaer A; De Koker S; Lambricht L; Uyttenhove C; Reschner A; Vanderplasschen A; Grooten J; Préat V
    Vaccine; 2015 Jun; 33(28):3179-85. PubMed ID: 25980430
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Early CD4+ T Cell Responses Are Associated with Subsequent CD8+ T Cell Responses to an rAd5-Based Prophylactic Prime-Boost HIV Vaccine Strategy.
    Lhomme E; Richert L; Moodie Z; Pasin C; Kalams SA; Morgan C; Self S; De Rosa SC; Thiébaut R
    PLoS One; 2016; 11(4):e0152952. PubMed ID: 27124598
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Safety and comparative immunogenicity of an HIV-1 DNA vaccine in combination with plasmid interleukin 12 and impact of intramuscular electroporation for delivery.
    Kalams SA; Parker SD; Elizaga M; Metch B; Edupuganti S; Hural J; De Rosa S; Carter DK; Rybczyk K; Frank I; Fuchs J; Koblin B; Kim DH; Joseph P; Keefer MC; Baden LR; Eldridge J; Boyer J; Sherwat A; Cardinali M; Allen M; Pensiero M; Butler C; Khan AS; Yan J; Sardesai NY; Kublin JG; Weiner DB;
    J Infect Dis; 2013 Sep; 208(5):818-29. PubMed ID: 23840043
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Safety, tolerability, and immunogenicity of influenza vaccination with a high-density microarray patch: Results from a randomized, controlled phase I clinical trial.
    Forster AH; Witham K; Depelsenaire ACI; Veitch M; Wells JW; Wheatley A; Pryor M; Lickliter JD; Francis B; Rockman S; Bodle J; Treasure P; Hickling J; Fernando GJP
    PLoS Med; 2020 Mar; 17(3):e1003024. PubMed ID: 32181756
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.